AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AUTO-1/22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AUTO-1NG is under development for the treatment of relapsed or refractory acute lymphoblastic leukemia, Burkitt lymphoma, acute myelocytic leukemia (AML, acute myeloblastic leukemia), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML, chronic myeloid leukemia), hairy cell leukemia, Hodgkin lymphoma (B-cell Hodgkin lymphoma) in pediatrics. It is a chimeric antigen receptor (CAR) T cell therapy comprising of CD19 CAR of AUTO-1 and a novel CD22 CAR. The drug candidate acts by targeting CD19 and CD22 expressing cancer cells.
Autolus Therapeutics overview
Autolus Therapeutics (Autolus), formerly Autolus Therapeutics is a clinical-stage biopharmaceutical company. It offers programmed T cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products includes Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programs. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, Greater London, the UK.
For a complete picture of AUTO-1/22’s drug-specific PTSR and LoA scores, buy the report here.